Colossal Biosciences
$10.2Bpaper valuation
// OVERVIEW
Colossal Biosciences is attempting to resurrect extinct species using CRISPR gene editing — a scientific ambition so audacious that its $10.2 billion valuation rests entirely on proving that Jurassic Park was science fiction that can become science fact. The company has announced woolly mammoth, Tasmanian tiger, and dodo restoration projects. It has not yet produced a single living de-extinct animal.
// HQ
Dallas, United States
// STATUS
PRIVATE
// FOUNDED
2021
// TIER
The Decacorns · $10B – $99B
// PRIMARY SECTOR
biotechnology
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
Colossal uses CRISPR gene editing to modify the genomes of living species' embryos — Asian elephants for mammoths, marsupials for thylacines — inserting genetic sequences reconstructed from degraded ancient DNA. The technical challenges are extraordinary: mammoth DNA is 4,000+ years degraded, elephant gestation is 22 months, and nobody has successfully edited a marsupial genome at scale. The company is effectively building the entire de-extinction technology stack from scratch while racing against a valuation that assumes success.
// WOWLS ASSESSMENT
The business model is unclear beyond 'create extinct animals and monetize intellectual property through genetics licensing and conservation technology.' No revenue is publicly disclosed. The founding team includes George Church — Harvard geneticist with genuine CRISPR credentials — and Ben Lamm, a serial entrepreneur whose previous ventures include Hypergiant, an AI company that pivoted three times. Colossal has raised approximately $235 million from investors including Peter Thiel's Founders Fund, Breyer Capital, and the CIA's venture arm In-Q-Tel. That capital buys runway to attempt something no lab has achieved: gestating a genetically engineered elephant embryo with mammoth traits to term. The company announced its mammoth project in 2021. Three years later the publicly documented milestone is: elephant stem cells with edited genes. Not embryos. Not pregnancies. Cells.
// WHY WOWLS HUNTS THIS
Because a $10 billion valuation on edited elephant cells is the Theranos playbook applied to conservation biology — except this time the technology might actually work, which makes the burn rate even more fascinating to watch. The CIA invested, which means someone thinks weaponized mammoth genetics is strategically interesting.
// VALUATION NOTE
The $10.2B valuation appears to be speculative or from secondary market estimates — no primary funding round at this valuation is publicly documented. Most recent confirmed primary round was $150M Series B in 2022 led by In-Q-Tel and Breyer Capital with no disclosed valuation.
VERDICT: VAPORWARE ASCENDANT — $10.2 BILLION VALUATION ON ZERO COMMERCIAL PRODUCTS, ZERO DE-EXTINCT ANIMALS, AND A TECHNICAL ROADMAP THAT REQUIRES SOLVING MULTIPLE PROBLEMS NOBODY HAS SOLVED BEFORE
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Colossal Biosciences.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Colossal Biosciences?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN